{"id":"immediate-high-intensity-statin","safety":{"commonSideEffects":[{"rate":"1-5","effect":"Muscle myalgia or myopathy"},{"rate":"1-3","effect":"Elevated liver transaminases"},{"rate":"2-4","effect":"Headache"},{"rate":"1-3","effect":"Gastrointestinal upset"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"High-intensity statins potently block the enzyme HMG-CoA reductase, which catalyzes an early rate-limiting step in hepatic cholesterol biosynthesis. This leads to upregulation of LDL receptors on hepatocytes, increasing clearance of LDL particles from the bloodstream and substantially reducing circulating LDL cholesterol. The immediate high-intensity formulation is designed for rapid onset of lipid-lowering effects in acute cardiovascular settings.","oneSentence":"Statins inhibit HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:40.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome or high-risk cardiovascular disease requiring rapid LDL cholesterol reduction"},{"name":"Hypercholesterolemia in patients requiring immediate intensive lipid lowering"}]},"trialDetails":[{"nctId":"NCT07432516","phase":"NA","title":"Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2026-02","conditions":"Coronary Artery Disease","enrollment":4400},{"nctId":"NCT03635749","phase":"PHASE3","title":"Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2018-09-17","conditions":"Acute Stroke, Transient Ischemic Attack","enrollment":6100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Immediate Atorvastatin"],"phase":"phase_3","status":"active","brandName":"Immediate high-intensity statin","genericName":"Immediate high-intensity statin","companyName":"Beijing Tiantan Hospital","companyId":"beijing-tiantan-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Statins inhibit HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels. Used for Acute coronary syndrome or high-risk cardiovascular disease requiring rapid LDL cholesterol reduction, Hypercholesterolemia in patients requiring immediate intensive lipid lowering.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}